Onkure Therapeutics (NASDAQ: OKUR) net income
Onkure Therapeutics reported a net loss of $59.5m for fiscal 2025; in fiscal 2024 it reported a net loss of $52.7m. Earnings per share were −$4.40.
Onkure Therapeutics's best year of the last 6 was fiscal 2020. It reported a loss in 6 of those 6 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$59.5m | — | −1,729.6% | −$4.40 |
| 2024 | −$52.7m | — | −2,616.6% | −$15.28 |
| 2023 | −$35.3m | — | −2,175.7% | −$124.41 |
| 2022 | −$52.0m | — | — | −$2.12 |
| 2021 | −$39.8m | — | — | −$2.19 |
| 2020 | −$19.5m | — | — | −$9.60 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Onkure Therapeutics net income compared with its sector
By net income for its latest fiscal year, Onkure Therapeutics ranks 274th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Onkure Therapeutics, −1,729.6%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 272nd | Nautilus Biotechnology | −$59.0m | — |
| 273rd | Adaptive Biotechnologies | −$59.5m | −21.5% |
| 274th | Onkure Therapeutics | −$59.5m | −1,729.6% |
| 275th | Climb Bio | −$59.9m | — |
| 276th | Contineum Therapeutics | −$60.0m | — |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Onkure Therapeutics
- How much did Onkure Therapeutics earn in fiscal 2025?
- Onkure Therapeutics reported a net loss of $59.5m for fiscal 2025. In fiscal 2024 it reported a net loss of $52.7m.
- What are the earnings per share of Onkure Therapeutics?
- They were −$4.40 in fiscal 2025, compared with −$15.28 in fiscal 2024.
- Where does Onkure Therapeutics rank in its sector by net income?
- It ranks 274th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Onkure Therapeutics come from?
- From the annual report (Form 10-K) that Onkure Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Onkure Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020. More on Onkure Therapeutics: the Onkure Therapeutics page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.